Aleksandra Bienia

Ms. Aleksandra Bienia

Department of Biophysics, Faculty of Biochemistry, Biophysics and Biotechnology Jagiellonian University in Cracow, Poland
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ABAleksandra Bienia
Aleksandra Bienia
OWOlga Wiecheć-Cudak
Olga Wiecheć-Cudak
AMAleksandra Anna Murzyn
Aleksandra Anna Murzyn
MKMartyna Krzykawska-Serda
Martyna Krzykawska-Serda
Cancer is one of the leading causes of death in humans. Despite the progress in cancer treatment, and an increase in the effectiveness of diagnostic methods, cancer is still highly lethal and very difficult to treat in many cases. Combination therapy, in the context of cancer treatment, seems to be a promising option that may allow minimizing treatment side effects and may have a significant impact on the cure. It may also increase the effectiveness of anti-cancer therapies. Moreover, combination treatment can significantly increase delivery of drugs to cancerous tissues. Photodynamic therapy and hyperthermia seem to be ideal examples that prove the effectiveness of combination therapy. These two kinds of therapy can kill cancer cells through different mechanisms and activate various signaling pathways. Both PDT and hyperthermia play significant roles in the perfusion of a tumor and the network of blood vessels wrapped around it. The main goal of combination therapy is to combine separate mechanisms of action that will make cancer cells more sensitive to a given therapeutic agent. Such an approach in treatment may contribute toward increasing its effectiveness, optimizing the cancer treatment process in the future.

18 February 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
EBEdyta Barańska
Edyta Barańska
OWOlga Wiecheć-Cudak
Olga Wiecheć-Cudak
MRMonika Rak
Monika Rak
ABAleksandra Bienia
Aleksandra Bienia
AMAnna Mrozek-Wilczkiewicz
Anna Mrozek-Wilczkiewicz
Maciej SerdaMaciej Serda
Maciej Serda
In recent years, carbon nanomaterials have been intensively investigated for their possible applications in biomedical studies, especially as drug delivery vehicles. Several surface modifications can modulate the unique molecular structure of [60]fullerene derivatives, as well as their physicochemical properties. For this reason, covalent modifications that would enable a greater water solubilization of the fullerene buckyball have been rapidly investigated. The most exciting applications of fullerene nanomaterials are as drug delivery vectors, photosensitizers in photodynamic therapy (PDT), astransfection or MRI contrast agents, antimicrobials and antioxidants. From these perspectives, the glucose derivatives of [60]fullerene seem to be an interesting carbon nanomaterial for biological studies. It is well-known that cancer cells are characterized by an increased glucose uptake and it has also been previously reported that the glucose transporters (GLUTs) are overexpressed in several types of cancers, which make them attractive molecular targets for many drugs. This study explored the use of a highly water-soluble glycofullerene (called Sweet-C60) in pancreatic cancer studies. Here, we describe the PANC-1 cell proliferation, migration, metabolic activity and glycolysis rate after incubations with different concentrations of Sweet-C60. The final results did not show any influence of the Sweet-C60 on various cancer cellular events and glycolysis, suggesting that synthesized glycofullerene is a promising drug delivery vehicle for treating pancreatic cancer.

23 June 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NWNorbert Wronski
Norbert Wronski
JWJan Wolnik
Jan Wolnik
WTWaclaw Tworzydlo
Waclaw Tworzydlo
ABAleksandra Bienia
Aleksandra Bienia
-G-Justyna Gogola-Mruk
-Justyna Gogola-Mruk
Agnieszka Wolnicka-GlubiszAgnieszka Wolnicka-Glubisz
Agnieszka Wolnicka-Glubisz
Melanoma is an aggressive cancer characterized by metabolic reprogramming that supports invasion and metastasis. Receptor-interacting protein kinase 4 (RIPK4) has been linked to tumor progression, but its role in melanoma metabolism remains unclear. This study examined whether RIPK4 is associated with melanoma aggressiveness through modulation of cellular bioenergetics. Previously generated RIPK4-knockout A375 and WM266.4 melanoma cell lines (CRISPR/Cas9) were used, and RIPK4 expression was restored by plasmid transfection. Cellular metabolism was assessed using the Seahorse XF Mito Stress Test in 2D monolayer cultures. In 3D spheroid models, ATP assays, qRT-PCR, and Western blotting were performed, together with functional analyses using 3D matrix invasion and CCID assays. In vivo relevance was evaluated by immunohistochemical analysis of RIPK4 and GLUT1 in lung metastases from NOD/SCID mouse xenografts. RIPK4 knockout induced a metabolically compromised state, characterized by reduced mitochondrial respiration and glycolysis, decreased HK2 and GLUT1 expression, and increased SDHB levels also impaired 3D invasive behavior, including reduced formation of invasive protrusions and decreased intravascular invasion. GLUT1 expression was detected in lung metastases but was reduced in RIPK4-deficient tumors. RIPK4 re-expression restored AKT phosphorylation and partially rescued HK2 and GLUT1 levels; however, metabolic flux (OCR/ECAR) was not recovered. These findings suggest that RIPK4 is associated with melanoma metabolic regulation and invasion, potentially involving AKT-linked signaling, but also indicate that additional mechanisms beyond AKT–GLUT1 contribute to the observed metabolic phenotype.